Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 04:44
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
Siemens Energy Secures €15 Billion Deal to Shore Up Finances
Imagine making shadowy data brokers erase your personal info. Californians may soon live the dream
Daversa Partners Secures No. 4 Spot on Fortune's 2023 Best Workplaces in New York List by Great Place to Work®
Asahi Kasei Begins Licensing of Design and Manufacturing Technology for Lithium-Ion Capacitor as Next-Generation Energy Storage Device
The River Rhine Is Starting to Dry Up Already — Two Weeks Into Summer
Tim Cook says Apple is building AI into ‘every product’ amid questions over its plans
Eptura’s Q2 Workplace Index Reveals Employees Rank Socialization and Collaboration as Top Motivator to Work from Office
Bitcoin Drops Below $27,000 as Market Liquidity Concerns Climb